Role of Monocytes in Heart Failure and Atrial Fibrillation

Shahid, Farhan; Lip, Gregory Y.H.; Shantsila, Eduard

doi:10.1161/jaha.117.007849

Cited by 86 publications

(74 citation statements)

References 209 publications

(228 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In neonatal cardiomyocytes, resveratrol suppresses LPS‐induced up‐regulation of CCL2 (Planavila et al, ). Lower expression of chemokines inhibits infiltration of large numbers of monocytes, which differentiate to excessive macrophages causing tissue damage, rather than tissue repair, in endothelium and myocardium (Shahid, Lip, & Shantsila, ). More specifically, lower expression of chemokines can attenuate monocyte adhesion onto endothelium, which is the initial event of atherogenesis.…”

Section: Molecular Basis Of Resveratrol Actionmentioning

confidence: 99%

Pharmacological basis and new insights of resveratrol action in the cardiovascular system

Cheng

Luo

Lau

et al. 2019

British J Pharmacology

112

View full text Add to dashboard Cite

Resveratrol (trans‐3,4′,5‐trihydroxystilbene) belongs to the family of natural phytoalexins. Resveratrol first came to our attention in 1992, following reports of the cardioprotective effects of red wine. Thereafter, resveratrol was shown to exert antioxidant, anti‐inflammatory, anti‐proliferative, and angio‐regulatory effects against atherosclerosis, ischaemia, and cardiomyopathy. This article critically reviews the current findings on the molecular basis of resveratrol‐mediated cardiovascular benefits, summarizing the broad effects of resveratrol on longevity regulation, energy metabolism, stress resistance, exercise mimetics, circadian clock, and microbiota composition. In addition, this article also provides an update, both preclinically and clinically, on resveratrol‐induced cardiovascular protection and discusses the adverse and inconsistent effects of resveratrol reported in both preclinical and clinical studies. Although resveratrol has been claimed as a master anti‐aging agent against several age‐associated diseases, further detailed mechanistic investigation is still required to thoroughly unravel the therapeutic value of resveratrol against cardiovascular diseases at different stages of disease development. Linked Articles This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc

show abstract

Section: Molecular Basis Of Resveratrol Actionmentioning

confidence: 99%

Pharmacological basis and new insights of resveratrol action in the cardiovascular system

Cheng

Luo

Lau

et al. 2019

British J Pharmacology

112

View full text Add to dashboard Cite

show abstract

“…Считается, что неклассические моноциты взаимосвязаны с популяцией резидентных тканевых макрофагов, имеют выраженные антиген-презентирующие свойства, активно синтезируют IL-1β, обладают высоким аффинитетом к эндотелию, но проявляют слабую фагоцитарную активность [6,7]. Их наиболее вероятной функцией в кровотоке является «патрулирование» эндотелия, так как неклассические моноциты способны элиминировать окисленные липиды, погибшие клетки и патогены с поверхности сосудистой стенки [16].…”

Section: Discussionunclassified

“…Чрезвычайно важно, что патогенез ИКМП до конца не изучен. В литературе обсуждается роль макрофагов в патогенезе ИКМП, а именно в индукции апоптоза кардиомиоцитов, пролиферации фибробластов и синтезе ими коллагенов с различными свойствами, в механизмах деградации интерстициального матрикса, а также в аутоиммунных процессах повреждения сердечной мышцы [4][5][6].…”

unclassified

“…Тканевые макрофаги, как известно, дифференцируются из моноцитов крови, среди которых в последнее время идентифицированы неклассические клетки (моноциты с иммунофенотипом CD14 + CD16 + ). Считается, что они обладают высоким аффинитетом к эндотелию и проявляют слабую фагоцитарную активность [6,7], поэтому могут играть важную роль в атеросклеротическом поражении сосудов сердца и развитии ИКМП. В связи с тем, что дифференцировка моноцитов и макрофагов на различные субтипы определяется цитокиновым профилем внеклеточного матрикса [8,9], содержание интерлейкинов (IL) и фактора некроза опухоли-альфа (TNF-α) в крови у больных ИБС с ИКМП могут влиять на численность неклассических моноцитов в циркуляции и детерминировать развитие данной патологии.…”

unclassified

See 1 more Smart Citation

Interleukin-10 and non-classical monocytes as biomarkers of ischemic cardiomyopathy

Шипулин¹,

Chumakova²,

Pogonchenkova³

et al. 2020

PKiK

View full text Add to dashboard Cite

Background. Chronic heart failure frequently occurs against the background of ischemic heart disease (IHD), and has also been associated with the diagnosis of ischemic cardiomyopathy (ICMP). While there are significant commonalities with respect to underlying mechanisms, it would be most important to identify differential diagnostic markers to facilitate diagnosis and verification at the early stages of disease.Aim. The intent of this study was to perform a quantitative assessment of non-classical monocytes in patients diagnosed with IHD with or without ICMP and to identify any relationships between non-classical monocytes and plasma concentrations of proinflammatory (interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF)-α) and anti-inflammatory (IL-4, IL-10, IL-13) cytokines.Methods. We examined 44 patients diagnosed with IHD, aged 49 - 63 years, with class II-III heart failure as per the New York Heart Association criteria. Of this group, 18 were also diagnosed with ICMP. The comparison group included 14 age-matched healthy controls. Percentages of non-classical (CD14+CD16+) monocytes in peripheral blood were determined by flow cytometry and the concentrations of IL-1β, IL-4, IL-6, IL-10, IL-13 and TNF-α were measured by enzyme-linked immunosorbent assay.Results. Amongst the patients diagnosed with ICMP, the concentration of IL-10 in blood plasma was higher than in those without this diagnosis, detected at 30.05 pg/ml (range 24.75 - 33.50 pg/ml, р=0.0412); the percentage of non-classical monocytes was lower, at 5.05% (range 4.08 - 6.58%, р=0.0094). Amongst patients diagnosed with IHD without ICMP, these parameters were within normal limits. The plasma concentrations of IL-1β, IL-6 and IL-13 in both groups were comparable to values obtained from healthy donors and IL-4 was undetectable throughout. Amongst patients diagnosed with ICMP, plasma TNF-α was detected at elevated levels that were comparable to those determined for patients diagnosed with IHD without ICMP.Conclusion. Imbalance of cytokines in blood in patients with coronary artery disease is characterized by excess TNF-α, absence of IL-4, and normal levels of IL-1β, IL-6 and IL-13, regardless of the type of ischemic myocardial injury. In patients with ICMP, we detected an overall decrease in the fraction of non-classical monocytes in association with an increase in plasma IL-10; these features were not detected in patients diagnosed with IHD without ICMP. As such, these biological responses may be used for timely diagnosis of ICMP.Received 27 May 2019. Revised 7 October 2019. Accepted 30 October 2019.Funding: The work is supported by grants of the Russian Foundation for Basic Research No. 18-015-00160\19 and the President of the Russian Federation No. НШ-2690.2018.7 and No. МД-2788.2019.7.Conflict of interest: Authors declare no conflict of interest.Author contributionsConception and study design: V.M. Shipulin, S.P. ChumakovaData collection and analysis: V.M. Shipulin, S.P. Chumakova, O.I. Urazova, M.V. Vins, V.V. NovickiyLiterature review: S.P. Chumakova, D.A. Pogonchenkova, A.S. PryakhinDrafting the article: S.P. Chumakova, D.A. Pogonchenkova, O.I. UrazovaCritical revision of the article: V.M. Shipulin, V.V. NovickiyStatistical analysis: S.P. ChumakovaFinal approval of the version to be published: V.M. Shipulin, S.P. Chumakova, D.A. Pogonchenkova, O.I. Urazova, M.V. Vins, A.S. Pryakhin, V.V. Novickiy

show abstract

“…При ýтом точно неизвестно, как соотносятся между собой субпопуляции моноцитов и макрофагов. Предполагается, что за счет классических моноцитов пополняется пул резидентных макрофагов, промежуточные клетки дифферен-цируются в DC миелоидного происхождения, а неклассические моноциты -в провоспалительные макрофаги [13].…”

Section: фенотипическая и функциональная гетерогенность моноцитов и мunclassified

Macrophages in bacterial lung diseases: phenotype and functions (review)

et al. 2019

View full text Add to dashboard Cite

This literature review is devoted to the analysis of the role of macrophages in the immunopathogenesis of infectious lung diseases of bacterial etiology. The article summarizes information about the origin of macrophages, their phenotypic and functional heterogeneity. The mechanisms of impaired protective function of innate immunity are associated with the polarization of the program of maturation and activation of macrophages in the direction to tolerogenic or immunoregulatory cells with phenotype of M2. Alveolar macrophages perform a variety of functions (from pro-inflammatory to regenerative) in the development of inflammation in the respiratory organs. Their inherent plasticity suggests that the same macrophages can change their phenotype and function depending on the microenvironment in the inflammatory focus at different stages of the disease. Understanding the mechanisms that regulate macrophage plasticity will be an important step towards realizing the potential of personalized immunomodulatory therapy.

show abstract

Role of Monocytes in Heart Failure and Atrial Fibrillation

Cited by 86 publications

References 209 publications

Pharmacological basis and new insights of resveratrol action in the cardiovascular system

Pharmacological basis and new insights of resveratrol action in the cardiovascular system

Interleukin-10 and non-classical monocytes as biomarkers of ischemic cardiomyopathy

Macrophages in bacterial lung diseases: phenotype and functions (review)

Contact Info

Product

Resources

About